4.7 Article

Immunoliposomes as an emerging nanocarrier for breast cancer therapy

期刊

EUROPEAN POLYMER JOURNAL
卷 184, 期 -, 页码 -

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.eurpolymj.2022.111781

关键词

Breast cancer; Immunoliposome; Liposome; Antibody; Nanocarriers; Chemotherapy; HER2; EGFR; HB-EGF

向作者/读者索取更多资源

Breast cancer is the most common non-cutaneous carcinoma in women and the second most prevalent tumour-related condition. Innovative nanotechnologies have shown promise in treating or targeting breast cancer. Recent research focuses on developing components that include drugs and target the site of illness. This article complements existing reviews on liposomal drug delivery by emphasizing immunoliposome tumour targeting and summarizing various experiments on therapeutic potential, liposomal parameters, and target site needs. Immunoliposomes are suggested as a promising therapeutic delivery device for breast cancer therapy, combining distinct target-cell associations and cytotoxic drugs.
The most prevalent non-cutaneous carcinoma in women and the second most prevalent tumour-related condition is breast cancer. There are significant therapeutic choices for treating breast cancer, and all come with adverse reactions. Innovative nanotechnologies showed promise for treating or focusing on breast cancer. Novel nanocarriers for the transport of chemotherapeutics were introduced by developments in protein engineering which completely changed nanomedicine. Recent research has focused on developing components that concurrently include drugs and targeting the site of illness. This article complements existing reviews on liposomal drug delivery by emphasising immunoliposome tumour targeting and summarising numerous experiments of immunoliposome assessment in vivo and in vitro with regard to therapeutic potential, structural liposomal parameters, and the needs of the target sites. Immunoliposomes have been suggested as a promising therapeutic delivery device for the therapy of breast cancer. In this review, we highlight current developments of immunoliposome formulation that synergistically demonstrate distinct target-cell associations while combining or loading with a variety of cytotoxic drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据